Mobia Medical, Inc. (MOBI)
NASDAQ: MOBI · Real-Time Price · USD
13.47
+1.27 (10.41%)
Nov 11, 2026, 4:00 PM EST - Market closed
Mobia Medical Earnings Call Transcripts
Fiscal Year 2026
-
Vivistim targets unmet stroke-recovery needs with an implant-plus-rehabilitation protocol, supported by guideline inclusion and a 2027 registry readout plan. 2027 payment at New Technology APC 1580 was affirmed as commercial expansion continues.
-
Q3 revenue grew 73% YoY to $15.6M, led by adoption in existing Vivistim programs. FY 2026 revenue guidance rose to $57.0M–$57.5M, while commercial expansion and guideline recognition support continued growth.
-
Q2 2026 revenue doubled year-over-year to $13.5M, driven by strong Vivistim adoption and territory expansion. IPO proceeds are fueling commercial growth, with full-year revenue guidance set at $54–$56M, reflecting 69–75% growth. Gross margin remains robust at 83.2%.